A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism
NCT ID: NCT06988670
Last Updated: 2025-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
35 participants
INTERVENTIONAL
2025-05-05
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
NCT06465108
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071
ADD-ON Study to Existing Hypoparathyroidism Studies
NCT00856401
A Phase 3 Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
NCT07081997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
EXT608 solution for injection, administered subcutaneously once-weekly, with multiple ascending doses (MAD) with a starting dose of 50 ug for 4 weeks, continuing to individualized dosing for 8 weeks
EXT608
Modified version of parathyroid hormone attached to vitamin D to extend half-life
Placebo
Placebo solution, administered subcutaneously once-weekly, with multiple ascending doses (MAD) with a fixed dose for 4 weeks, continuing to variable dosing for 8 weeks
Placebo
Placebo for injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EXT608
Modified version of parathyroid hormone attached to vitamin D to extend half-life
Placebo
Placebo for injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. An understanding, ability, and willingness to fully comply with study procedures and restrictions.
3. Male or female between 18 and 65 years of age. Male participants with female partners of child bearing potential must agree to use barrier contraception, e.g., condoms plus spermicide, from administration of the study drug until at least 3 months after administration of the study drug. Abstinence from heterosexual intercourse from administration of study drug until at least 3 months after administration of study drug is acceptable if it is in accordance with the participant's lifestyle. Female participants should be either surgically sterile (had a bilateral tubal ligation, bilateral salpingectomy, bilateral oophorectomy, or hysterectomy), postmenopausal (defined as 12 months with no menses prior to screening and a serum follicle stimulating hormone in the postmenopausal range at screening), or, if of child bearing potential, must be non-lactating and willing to use a highly effective method of birth control for 30 days prior to administration of study drug and agree to continued use of this method until at least 3 months after administration of study drug.
4. Participants have a history of hypoparathyroidism for 12 months at least, with PTH levels below the LLN with concomitant serum calcium \< 9 mg/dL.
5. Participants are treated with a daily dose \> 750 mg elemental calcium if using \> 0.25 µg/day calcitriol, or a daily dose \> 1000 mg elemental calcium if not using calcitriol.
6. Participants have normal blood levels of 25-hydroxyvitamin D (i.e. \> 20 ng/dL or \> 75 nmol/L) and not above 1.5 times the upper limit of normal.
7. Participants have normal thyroid test results for 3 months at least while taking a stable dose of thyroid medication or no medication.
8. Participants have a BMI \< 35 kg/m2.
9. Albumin-adjusted serum calcium level should be between the lower half and the middle of the normal range upon randomization into the study.
Exclusion Criteria
2. Unwillingness to use a diary deployed on a smartphone daily for recording vitamin D, active vitamin D, calcium, magnesium and study drug doses as well as periodic symptom reporting.
3. Participants with a history of neoplasia (except thyroid cancer) with no sign of recurrence 5 years after diagnosis.
4. Participants with a history of or active GI tract disease that may impact the absorption of calcium (e.g. malabsorption).
5. Participants with a history of severe hypocalcemia leading to seizures or cardiac arrhythmias within 6 months prior to screening.
6. Participants with chronic kidney disease (eGFR \< 30 ml/min) or active nephrolithiasis (needing pain medication in the last 6 months).
7. Participants taking the following medications within the respective exclusion period:
* Proton pump inhibitors (4 weeks)
* Bisphosphonates (3 months)
* Parathyroid hormone, PTH analogs (6 months)
* Thiazide diuretics (14 days)
* Calcitonin or calcinet hydrochloride (3 months)
8. Participant has increased CV proarrhythmic potential:
1. Participant has a QT interval with Fridericia's correction method (QTcF) \>450 ms or PR outside the range of 120 to 220 ms, confirmed with one repeat testing, at the Screening Visit or Inpatient Check-in (Day -1) Visit.
2. A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
3. The use of concomitant medications that prolong the QT/QTc interval.
9. Chronic/severe cardiac disease including, but not limited to, cardiac insufficiency, unstable angina, arrhythmias, bradycardia (resting heart rate \<60 beats/minute), or hypotension (systolic and diastolic blood pressures \<100 and 60 mmHg, respectively).
10. Any condition or disease that, in the opinion of the investigator, may interfere with a participant's participation or may confound the interpretation of safety or efficacy in the study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Extend Biosciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Trial Site
Buenos Aires, Buenos Aires F.D., Argentina
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.